How Do ED Injections (Tri-Mix, Bi-Mix) Actually Work?

Short answer: Tri-Mix and Bi-Mix combine vasoactive drugs that relax cavernosal smooth muscle and increase blood flow. Only alprostadil is FDA-approved for intracavernosal ED use — the combinations are compounded and unlicensed.

Injectable ED therapy sounds intimidating, but the science behind it is well established and dates back more than 40 years. Here's what's actually in trimix and bimix injections, how each component works, and — importantly — which parts of this therapy carry real regulatory approval and which don't.

What's Actually in the Injection

Tri-Mix and Bi-Mix are compounded combinations of the same core vasoactive drugs. Tri-Mix combines papaverine, phentolamine, and alprostadil (prostaglandin E1); Bi-Mix drops alprostadil and uses just papaverine and phentolamine.^[3] Each drug works through a different mechanism:

• Alprostadil — a synthetic prostaglandin E1 analog that relaxes cavernosal smooth muscle and dilates cavernosal arteries by raising intracellular cyclic AMP, directly increasing blood flow into the penis when injected into the erectile tissue.^[2]
• Papaverine — a nonspecific phosphodiesterase inhibitor that raises cyclic AMP and cyclic GMP in cavernosal smooth muscle, producing local vasodilation that increases arterial inflow and reduces venous outflow.^[4]
• Phentolamine — a non-selective alpha-adrenergic blocker that reduces sympathetic vasoconstrictive tone in the penis, lowering resistance to relaxation and enhancing the effect of papaverine and alprostadil when combined.^[4]

Despite different targets, all three converge on the same physical endpoint: relaxed cavernosal smooth muscle and dilated arteries increase blood inflow, which then gets trapped in the penis as the engorged tissue compresses the surrounding veins — producing a rigid erection.^[11]

Where This Therapy Came From

Papaverine was the first effective intracavernosal injection for ED, introduced in the early 1980s and later combined with phentolamine in a 30:1 ratio. These early mixtures were effective and cheap, but carried a meaningfully higher risk of prolonged erections and priapism than what came later.^[8] An early trial of papaverine plus phentolamine in 100 men with organic ED found functional erections in 100% of men with neurogenic causes, 65.7% with vascular causes, and 90% with undetermined causes — with 79.5% of responders choosing to continue self-injection, and only four patients experiencing a sustained erection requiring intervention.^[8]

When alprostadil (prostaglandin E1) was later introduced and licensed, it became the primary monotherapy for intracavernosal injection because it produced effective erections with fewer complications than papaverine alone — and it's remained a first-choice agent for many patients ever since.^[9] The pivotal 1996 New England Journal of Medicine trial — 683 men over six months of self-injection — found successful sexual activity after 94% of injections, concluding the therapy was effective and tolerable across a wide range of underlying causes.^[6] A broader review of 15 years of clinical experience with these injectable agents found overall efficacy rates above 85%.^[5]

What to Expect and What the Risks Are

The FDA's Caverject label describes alprostadil as indicated for ED of neurogenic, vasculogenic, psychogenic, or mixed origin, with penile pain as the most common side effect and prolonged erection or priapism as the more serious risks to watch for.^[10]Contemporary clinical reviews are consistent on where this fits in treatment: oral PDE5 inhibitors remain first-line therapy, but intracavernosal injection — alprostadil alone or compounded combinations like Tri-Mix — is recommended by major urology guidelines as a safe, effective second-line option for men who don't respond adequately to oral medication, provided careful patient selection, counseling, and dose titration are used to limit risks like priapism and tissue scarring.^[7]

The Bottom Line

ED injections work through well-understood, decades-old pharmacology with strong efficacy data behind them. The regulatory picture is worth knowing clearly, though: alprostadil alone carries real FDA approval and EAU-guideline backing, while trimix and bimix — despite being widely used and reporting strong real-world efficacy — have never been licensed by any major regulatory body. That doesn't make them illegitimate; compounding under a patient-specific prescription is legal. But it's a distinction worth expecting any provider offering trimix to be upfront about, rather than presenting it as an approved product.

If ED injections are on your radar, compare how different Men's Health providers structure this option on RENVA's hub and what they disclose about licensing and compounding.

Frequently Asked Questions